Bubley GJ - Search Results

1

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Fenton MA, et al. Among authors: bubley gj. Clin Cancer Res. 1997 Aug;3(8):1383-8. Clin Cancer Res. 1997. PMID: 9815822

2

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Taplin ME, et al. Among authors: bubley gj. N Engl J Med. 1995 May 25;332(21):1393-8. doi: 10.1056/NEJM199505253322101. N Engl J Med. 1995. PMID: 7723794 Free article.

3

Treatment of metastatic prostate cancer. Lessons from the androgen receptor.

Bubley GJ, Balk SP. Bubley GJ, et al. Hematol Oncol Clin North Am. 1996 Jun;10(3):713-25. doi: 10.1016/s0889-8588(05)70363-4. Hematol Oncol Clin North Am. 1996. PMID: 8773507 Review.

4

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. Joyce R, et al. Among authors: bubley gj. J Urol. 1998 Jan;159(1):149-53. doi: 10.1016/s0022-5347(01)64039-4. J Urol. 1998. PMID: 9400459

5

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Taplin ME, et al. Among authors: bubley gj. Cancer Res. 1999 Jun 1;59(11):2511-5. Cancer Res. 1999. PMID: 10363963

6

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. Ko YJ, et al. Among authors: bubley gj. Clin Cancer Res. 2001 Apr;7(4):800-5. Clin Cancer Res. 2001. PMID: 11309325 Clinical Trial.

7

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.

Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP. Chott A, et al. Among authors: bubley gj. Am J Pathol. 1999 Oct;155(4):1271-9. doi: 10.1016/S0002-9440(10)65229-7. Am J Pathol. 1999. PMID: 10514409 Free PMC article.

8

Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Stanbrough M, et al. Among authors: bubley gj. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8. doi: 10.1073/pnas.191235898. Epub 2001 Sep 4. Proc Natl Acad Sci U S A. 2001. PMID: 11535819 Free PMC article.

9

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE. Taplin ME, et al. Among authors: bubley gj. Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9. doi: 10.1016/s0093-7754(01)90152-6. Semin Oncol. 2001. PMID: 11685726 Clinical Trial.

10

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Tahir SM, et al. Among authors: bubley gj. J Immunol. 2001 Oct 1;167(7):4046-50. doi: 10.4049/jimmunol.167.7.4046. J Immunol. 2001. PMID: 11564825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters